GSK, Adaptimmune Therapeutics expand cancer immunotherapy alliance
The companies signed a collaboration and licensing agreement in June 2014 for about five programs, including the lead NY-ESO TCR program. GSK can license the program if it
The companies signed a collaboration and licensing agreement in June 2014 for about five programs, including the lead NY-ESO TCR program. GSK can license the program if it
Mission Therapeutics was established in 2011 to commercialize expert research into the ubiquitin pathway to treat cancers and other unmet medical needs. The company built a platform to
Kathy Niakan, a group leader at the Francis Crick Institute in London, will lead the research and use the CRISPR-Cas9 genome-editing technique in healthy human embryos. The researchers
The company’s vaccines division, Sanofi Pasteur, will use its expertise in developing vaccine for the virus. Sanofi Pasteur has developed vaccines against viruses in the same family as
The company expects to commence phase 1/2 clinical trial in the second quarter of this year. AP32788 is an internally discovered product candidate designed as a targeted therapy
In Europe, Coagadex (human coagulation factor X) is indicated for the treatment and preventive management of bleeding episodes and the control of bleeding during surgical procedures in patients
The companies did not disclose the financial terms of the transaction, under which Allergan will maintain marketing rights for the product in the US and Canada. AstraZeneca will
The meeting will be held on 29th March. Last November, the FDA classified the Nuplazid NDA as having priority review status with a target prescription drug user fee
The results from the initial trial are anticipated in the middle of this year, with the results from the second study expected soon thereafter. The FIT program features
The MoC with the Iran Food and Drug Administration, affiliated to the Ministry of Health and Medical Education, is aimed at initiating talks to explore the possibilities in